Dr. Tse-Wen Chang, President and CEO

Please see Founder.

Dr. Hsing-Mao Art Chu, Vice President of R&D

Dr. Chu obtained his B.Sc. degree from Chang Gung University, M.Sc. degree from National Yang-Ming University, and Ph.D. degree from National Taiwan University. 

He started his postdoctoral research in the Institute of Biological Chemistry, Academia Sinica, and joined Dr. Chang’s laboratory in the Genomics Research Center, Academia Sinica in 2011 to study various antibody engineering methodologies and to work on CemX and anti-CemX antibodies.


He joined Immunwork as the Director of Research in January 2015 and was promoted to V.P. of R&D in 2019.

Ms. Ying-Rong Lai, Vice President of Administration & Executive Assistant

Ms. Lai obtained her B.Sc. degree from Chung Hua University and Master degree in Biotechnology Management from National Taiwan University.

She held managerial positions while working in several business sectors. From 2004 to 2014, she was a key manager of investment at Taishin International Commercial Bank and at Yuanta Commercial Bank and won a number of service excellence awards. 

In 2014, she joined Immunwork as Director of Administration, and was promoted to V.P. of Administration in 2021.

Dr. Chi-Jiun Peng, Senior Manager, Process Development and CMC

Dr. Peng received his B.Sc. and M.Sc. degree from Yang-Ming University in 1999 and 2001.

He then  joined the Tri-Service General Hospital as a radiochemist in charge of new drug development, clinical drug production, and clinical trials. In 2013, he joined Super Laboratory Inc. as Director of the Analytical Chemistry Laboratory. In 2014, he began Ph.D. studies in the Department of Chemistry, National Taiwan University doing research on glycoprotein vaccines. 

After receiving Ph.D. in 2019, he joined Immunwork as a manager responsible for CMC and manufacturing.


Dr. Pei-Min Chen, Senior Manager, Drug Development and Regulatory Affairs

Dr. Chen received her Ph.D. degree in microbiology from National Taiwan University and had 6 years of industry experience in drug translational development working in CAP-accredited medical laboratories.

Before joining Immunwork in 2021, she was the Director of Preclinical and Clinical Research at United Biomedical, Inc., Asia, responsible for the development of two peptide-based human vaccines (an immunotherapeutic vaccine and a COVID-19 vaccine).

Dr. Chen has ample experience in GLP- and GCLP-compliant studies, pre-IND meetings, and IND applications for first-in-human clinical trials.

Dr. Kun-Po Li, Manager, External Collaboration and Clinical Development

Dr. Li received B.Sc. and M.Sc. degrees from National Taiwan University and Ph.D. degree in Immunology from University of Cincinnati.

Before joining Immunwork in 2020, Dr. Li worked at the Greater Boston Campus of Sanofi, where he was a project manager, leading translational medicine studies of multiple products in immuno-oncology, autoimmune, and rare diseases therapeutic areas.

Prior to Sanofi, Dr. Li worked at Compass Therapeutics, Inc. to support research of therapeutic antibodies and bi-specific antibodies. In Immunwork, Dr. Li is responsible for external collaboration.


Dr. Allen Yueh-Hsiang Yu, Project Manager, Oncology Programs

Dr. Yu received his B.Sc. and M.Sc. degrees from National Tsing Hus University in 2000 and 2002, and Ph.D. from National Defense Medical University in 2012.

He then started his postdoctoral research in the Genomic Research Center, Academia Sinica, and was responsible for estalishing a single B-cell cloning platform and identifying various antibodies against infectious diseases. 

In 2019, Allen was hired as an associate research fellow in Immunwork and was promoted to a project manager in 2020 responsible for oncological programs.


Dr. Wendy Mun-Teng Wong, Project Manager, Endocrinology Programs

Dr. Wong received her B.Sc. degree in Biomedicine in 2008 and Ph.D. in Biomedicine (Molecular and Cellular Biology) in 2013 from Universiti Sains Malaysia.

She did postdoctoral research on HCV replication pathway at the Institute of Biomedical Sciences, Academia Sinica in 2013-17.

Dr. Wong was recruited as associate research fellow in Immunwork in 2018 and was promoted to a project manager for programs on diabetes, obesity, and fatty liver diseases in 2020.


Dr. Ting Chen, Manager, Strategy of Product Portfolio

Dr. Chen received her B.Sc. degree from National Taiwan Normal University in 2001, M.Sc. degree from National Taiwan University in 2003, and Ph.D. degree from National Tsing Hua University in 2010.

Before joining Immunwork in 2022, she did postdoctoral research on drug development against enterovirus A71 and SARS-CoV-2 at the Institute of Biomedical Sciences, Academia Sinica.

In her current position, Dr. Chen is responsible for communication with government agencies, planning investor awareness matters, and helping product portfolio strategies.



Dr. Cédric Grauffel, Manager, T-E Drug Molecular Design

Dr. Grauffel received his Ph.D. in Chemistry at the University of Strasbourg, France in 2009 and did postdoctoral research on peripheral membrane proteins and protease inhibitors in the University of Bergen, Norway in 2010-13.

He came to the Institute of Biomedical Sciences, Academia Sinica in 2013, where he worked on metal competition in proteins and aspects of drug design until 2022, when he was hired by Immunwork as a manager in charge of the design of a new generation of T-E pharmaceuticals.